DYN vs FULC
DYN: Dyne Therapeutics is a clinical-stage biotechnology company developing targeted muscle therapeutics for rare diseases using its proprietary FORCE platform. FULC: Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on unlocking gene expression to treat serious, rare genetic diseases.
Side-by-side fundamentals
| Metric | DYN | FULC | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $25.18 | $3.58 | |
| Market cap as of 2026-08-03 | $4.7B | $273M | |
| Net margin as of 2026-08-03 | n/a | +8.1% | |
| Operating margin as of 2026-08-03 | n/a | -3.6% | |
| ROE as of 2026-08-03 | -58.3% | -22.5% | FULC higher |
| ROA as of 2026-08-03 | -46.8% | -21.2% | FULC higher |
| Debt / equity as of 2026-08-03 | 0.18 | 0.00 | FULC lower |
| Beta as of 2026-08-03 | 1.79 | 1.34 | |
| 1-year return as of 2026-07-31 close | +155.6% | -46.8% | DYN higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.